Ny oppdatert digital produktpresentasjon av Abilify Maintena® (aripiprazol)



  1. Abilify Maintena® SPC 10/2020 avsnitt 4.1.
  2. Abilify Maintena® SPC 10/2020, avsnitt 4.2
  3. Tiihonen J, Haukka J, Taylor M et al. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization  for Schizophrenia. Am J Psychiatry 2011;168:603–609)
  4. Abilify Maintena® SPC 10/2020, avsnitt 4.8
  5. Fleischhacker WW, Sanchez R, Perry PP et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry 2014;205:135–144,
  6. Hasan A, Falkai P, Wobrock T et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44.
  7. Corell C, Citrome L, Haddadd PM et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry 2016;77(suppl 3):1-24.
  8. Drake RE, Whitley R. Recovery and severe mental illness: description and analysis. Can J Psychiatry 2014; 59(5):236-42.
  9. Cechnicki A, Hanuszkiewicz I, Polczuk R. Prognostic value of duration of untreated psychosis in long-term outcome of schizophrenia;Med Sci Monit, 2011; 17(5): CR277-283.
  10. Gutiérrez-Casares, Canas F, Rodriguez-Morales. A Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study CNS Spectrums 2010; 15: 327-337.
  11. Nickl-Jockschat, Schneider F, Pagel AD. Progressive pathology is functionally linked to the domains of language and emotion: meta-analysis of brain structure changes in schizophrenia patients Eur Arch Psychiatry Clin Neurosci. 2011 Nov;261 Suppl 2:S166-71.
  12. Nazrallah Research Review. A More Rational Paradigm for Treating Schizophrenia September 2010. www.researchreview.co.nz.
  13. Tiihonen J, Haukka J, Taylor M. A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia Am J Psychiatry 2011;168:603–609.
  14. Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (Cambridge Medicine). 4th ed. NY, USA: Cambridge University Press.
  15. Lieberman JA, Perkins D, Belger A et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884–897.
  16. Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. J Clin Psychiatry 2006;67:983–990.
  17. Gorna K, Jaracz K, Jaracz J et al. Social functioning and quality of life in schizophrenia patients --relationship with symptomatic remission and duration of illness. Psychiatr Pol 2014;48:277–288.
  18. Kane JM, Sanchez R, Perry PP et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.  J Clin Psychiatry 2012;73:617–624.
  19. Kane JM,  Zhao C, Johnsons BR et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis. J Med Econ 2015;18:145–154.
  20. Naber D, Hansen K, Forray C et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia Schizophren Res 2015;168: 498-504
  21. Citrome L. New second-generation long acting injectable antipsychotics for the treatment of Schizophrenia Expert Rev. Neurother. 2013;13(7): 767-783
  22. Falissard B, Sapin C, Loze Y et al. Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS) Int J Methods Psychiatr Res 2016;25:101–111.
  23. ABILIFY® SPC 09/2020 avsnitt 4.1.
  24. ABILIFY® injeksjonsværske SPC 09/2020 avsnitt 4.1.
  25. Abilify Maintena® SPC 10/2020, avsnitt 4.2.
  26. Abilify Maintena® SPC 10/2020, avsnitt 4.8.
  27. Abilify Maintena® SPC 10/2020, avsnitt 4.4.
Du forlater Progress in Mind
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
Informasjonen på dette nettstedet er utelukkende ment for helsepersonell
Register for access to Progress in Mind in your country